v3.22.4
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of stock-based compensation expense
         
   Year Ended December 31, 
   2022   2021 
Research and development  $1,153   $907 
General and administrative   1,965    1,893 
Selling and Marketing   249    173 
   $3,367   $2,973 
Schedule of assumptions
         
   Year Ended December 31, 
   2022   2021 
Weighted average exercise price:  $14.21   $22.05 
Weighted average grant date fair value per share:  $10.37   $15.49 
Assumptions:          
Expected volatility   83.18%    81.11% 
Weighted average expected term (in years)   6.51    6.34 
Risk-free interest rate   1.96%    1.05% 
Expected dividend yield   0.0%    0.0% 
Schedule of stock option activity
                 
  

Number of

Shares

  

Weighted-

Average

Exercise

Prices

  

Weighted-Average

Remaining

Contractual

Term
(In Years)

   Intrinsic Value 
Outstanding at January 1, 2022   2,869   $6.64           
Granted   196   $14.21           
Exercised   (45)  $5.38           
Forfeited   (3)  $28.66           
Expired   (8)  $33.09           
Outstanding at December 31, 2022   3,009   $7.07    5.07   $2,249 
Exercisable at December 31, 2022   2,585   $6.45    4.57   $1,837 
Schedule of restricted stock option activity
         
   Number of Shares   Weighted-Average Grant Date Fair Value 
Outstanding at January 1, 2022   386   $6.75 
Granted   194   $14.41 
Vested   (240)  $7.22 
Outstanding non-vested shares at December 31, 2022   340   $10.78